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studies is present and real, we have developed a liquid chromatography

the syringe pump at a flow rate of 10 μL min 1. The optimized param-

tandem mass spectrometry method in this work for quantitative deter-

eters were as follows: curtain gas at 45 psi; collision gas at 3 psi; ion

mination of MLN0128 in human plasma to support the clinical develop-

spray voltage at 5500 V; temperature at 600°C; ion source gas 1 at

ment of the drug. The method developed has been validated according

55 psi; ion source gas 2 at 45 psi; declustering potential at 60 V;

to the US Food and Drug Administration (US‐FDA, 2001) guidance for

entrance potential at 7.5 V; collision energy at 35 eV; collision cell exit

industry on bioanalytical method validation with the intention to be

potential at 4 V; and resolution at 0.7 units. Quantitation of MLN0128

used for pharmacokinetic study of MLN0128 in clinical trials.

and IS was done in multiple‐reaction‐monitoring (MRM) mode with the
mass transitions, m/z 310 → 268 for MLN0128, and m/z 226 → 127
for the IS, respectively, using a dwell time of 400 ms for each analyte.

EXPERIMENTAL

Preparation of stock and working solutions

Chemicals
MLN0128 {3‐(2‐aminobenzo[d]oxazol‐5‐yl)‐1‐isopropyl‐1H‐pyrazolo
[3,4‐d]

pyrimidin‐4‐amine,

C15H15N7O}

was

purchased

from

Selleckchem (Houston, TX, USA) (catalog no. S2811, purity >99.64%).
STK040263

{1‐benzyl‐1H‐pyrazolo

[3,4‐d]pyrimidin‐4‐amine,

C12H11N5} (as internal standard, IS, purity >90%) was purchased from
Vitas‐M Laboratory (Apeldoorn, Netherlands). LC/MS‐grade methanol
(MeOH), LC/MS‐grade acetonitrile, HPLC‐grade water, HPLC‐grade
methyl tert‐butyl ether (MTBE) and ACS‐grade dimethylsulfoxide were
purchased from Fisher Scientific (Pittsburgh, PA, USA). Ammonium
formate was from Sigma‐Aldrich (St Louis, MO, USA). Blank pooled
human plasma and six individual lots of blank human plasma with
specific

lot

numbers

(IR11–1670,

1 M2070–01,

1 M2070–02,

1 M2070–03, 1 M2070–04, 1 M2070–05 and 1 M2070–06) were
purchased from Innovative Research (Novi, MI, USA).

The stock solutions of MLN0128 (1.00 mg mL 1) and IS (1.00 mg mL 1)
were prepared as follows: MLN0128 and the IS (1 mg or more) were
weighed out precisely on a Mettler Toledo (Greifensee, Switzerland)
XS20 model analytical balance to 0.01 mg, and each standard compound dissolved in an appropriate volume of dimethylsulfoxide to
make a concentration of 1.00 mg mL 1. These stock solutions were
kept in a freezer at −20°C before use. The working solutions of
MLN0128 (1.00 μg mL 1) and the IS (1.00 μg mL 1) were freshly prepared by serial dilution of each stock solution with the mobile phase.
The stock solution of ammonium formate (0.100 M) was prepared
by dissolving appropriate amount of ammonium formate salt in a
known volume of HPLC‐grade water and stored in a refrigerator at
4°C before use. The working solution of ammonium formate
(10.0 mM) was prepared by a 10‐fold dilution of the stock solution with
HPLC‐grade water and adjusted to pH 2.8 using formic acid, if
necessary.

Instrumentation
The liquid chromatography tandem mass spectrometry (LC–MS/MS)
system used in this work consisted of a Shimadzu (Columbia, MD,
USA) Prominence UFLC unit with a controller (CBM‐20 A), two binary
pumps (LC‐20 AD) and an autosampler (SIL‐ 20 AC), and an AB Sciex
(Foster City, CA, USA) API3200 turbo‐ion‐spray® triple quadruple
tandem mass spectrometer equipped with an electrospray ionization
(ESI) probe and a syringe pump. The LC–MS/MS system was
controlled by AB Sciex Analyst® (version 1.5.1) software for its
operation, data acquisition and processing.

Preparation of standard solutions
The standard solutions of MLN0128 (1.00, 2.00, 2.50, 5.00, 10.0, 25.0,
30.0, 50.0, 100, 200, 250, 300, 400 and 500 ng mL 1) were prepared
daily by sequential dilution of the working solution with the mobile
phase to make higher concentrations of the standard solutions
(e.g. 100, 200, 250, 300, 400 and 500 ng mL 1) and by serial dilutions
of these standard solutions with the mobile phase to make lower
concentrations of the standard solutions (e.g. 1.00, 2.00, 2.50, 5.00,
10.0, 25.0, 30.0 and 50.0 ng mL 1). The standard solution of the IS at
concentration of 50 ng mL

Liquid chromatography

1

was prepared freshly by direct dilution

of working solution of the IS with the mobile phase.

Chromatographic separation of MLN0128 and the IS was carried out
isocratically at room temperature on a Waters (Milford, MA, USA)
XTerra® MS C18 column (2.1 × 50 mm, 3.5 μm) connected to a Waters
XTerra® MS C18 guard column (2.1 × 10 mm, 3.5 μm) with mobile
phase

consisting

of

methanol–acetonitrile–ammonium

Preparation of plasma calibrators and quality
controls

formate

Plasma MLN0128 calibrators (0.100, 0.200, 0.500, 1.00, 2.50, 5.00,

(10.0 mM, pH 2.8; 34:6:60, v/v/v) pumped at a flow rate of

10.0, 25.0 and 50.0 ng mL 1) were prepared by mixing 10.0 μL of each

1

0.300 mL min . Acetonitrile was used as the wash solvent between

MLN0128 standard solution (1.00, 2.00, 5.00, 10.0, 25.0, 50.0, 100,

injections. For each analysis, 10.0 μL of sample was injected into the

250 and 500 ng mL 1) with 90.0 μL of blank pooled human plasma.

system by autosampler set at 4°C, and the total run time was 4 min.

The zero calibrator (or single blank plasma) was prepared by mixing
10.0 μL of the mobile phase with 90.0 μL of blank pooled human

Tandem mass spectrometry

plasma. Plasma MLN0128 quality controls (QCs) (0.25, 3.00 and

Mass spectrometric detection was carried out using positive

40.0 ng mL 1) were prepared by mixing 10.0 μL of each MLN0128

electrospray ionization (ESI+) mode, which was tuned for compound‐

standard solution (2.50, 30.0 and 400 ng mL 1) with 90.0 μL of blank

dependent and source‐dependent parameters by separate infusion of

pooled human plasma. The plasma MLN0128 calibrators and QCs

MLN0128 (500 ng mL 1) and IS (500 ng mL 1) in the mobile phase by

were stored at −20°C before use.
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Plasma sample preparation
Plasma samples (e.g. calibrator and QC) were thawed to room temperature and placed in disposable borosilicate glass tubes (13 × 100 mm)

three concentrations (0.250, 3.00 and 40.0 ng mL 1) with a fixed
concentration of the IS (5.00 ng mL 1) were prepared in the pooled
and the extracted pooled human plasma matrices.

from VWR (Radnor, PA, USA). For each 100 μL of plasma sample,

Linear calibration curve

10.0 μL of the IS (50.0 ng mL 1) were added except the double blank
plasma where 10.0 μL of the mobile phase were added. After vortexing
for 30 s, 2 mL of MTBE were added to the sample tube, and the liquid
phases were mixed in a multi‐tube vortex mixer (Troemner, Thorofare,
NJ, USA) for 5 min to extract the analytes, then centrifuged in a Sorvall
ST40R centrifuge (Thermo Scientific, Waltham, MA, USA) at 4816 × g
at 4°C for 8 min. The organic phase (upper layer) was transferred into
a fresh borosilicate glass tube and dried in a TurboVap® LV evaporator
(Caliper Life Sciences, Hopkinton, MA, USA) at 30°C under nitrogen

MLN0128 calibration curve was constructed using nine non‐zero
plasma calibrators, one single‐blank (with the IS only), and one
double‐blank plasma (without MLN0128 or the IS). The concentrations
of non‐zero calibrators were 0.100, 0.200, 0.500, 1.00, 2.50, 5.00,
10.0, 25.0 and 50.0 ng mL

1

with the IS concentration of 5.00 ng mL 1.

The peak area ratios of MLN0128 to the IS (y) were plotted vs
the concentrations of MLN0128 plasma calibrators (x) with 1/x
weighting.

gas at a pressure of 20 psi for 12 min. The resultant dried residue

Accuracy, precision and dilution study

was reconstituted in 100 μL of a reconstitution solution containing
methanol and 10 mM ammonium formate (pH 2.8) (1:9, v/v) for the

In this work, the intra‐assay accuracy and precision were determined

subsequent LC–MS/MS analysis.

using five replicate injections of QC samples at three different
concentrations (0.250, 3.00 and 40.0 ng mL 1). The inter‐assay

Method validation

accuracy and precision were determined using five parallel injections
from five identical QCs at three different concentrations (0.250, 3.00

The method developed was validated in human plasma following the

and 40.0 ng mL 1) in three separate days. Dilution study was

US Food and Drug Administration guidance for industry on

conducted using QC concentration at 250 ng mL 1, which was 5 times

bioanalytical method validation in terms of selectivity, lower limit of

beyond the upper limit of the linear calibration curve (50 ng mL 1), and

quantitation, matrix effect, recovery, linear calibration range, accuracy

the analysis was carried out after 10‐fold dilution of plasma dilution

and precision, as well as stabilities for short‐term sample processing

QC by the pooled blank human plasma.

and long‐term sample storage.

Stability studies
Selectivity and lower limit of quantitation

The stabilities of the MLN0128 stock solution (1.00 mg mL 1) and

The selectivity of this method was assessed by any interferents

plasma QCs (0.250 and 40.0 ng mL 1) were investigated against test

observed at the retention times and mass transitions of MLN0128

controls at the same concentrations prepared freshly on the day of

and the IS in six individual blank human plasma and blank pooled

the experiment. The stability of MLN0128 was determined from five

human plasma matrices. The lower limit of quantitation (LLOQ) of

replicates by comparing the mean‐peak‐area ratio of MLN0128 to

the method was defined as the lowest concentration of MLN0128

the IS in a test sample with that of the test control, and multiplying

plasma calibrator with accuracy expressed as percent relative error

by 100%.

(RE) and precision expressed as percentage coefficient of variation

In the stability studies, the stock solution was kept on bench‐top

(CV) at ≤ ± 20 and ≤20%, which was validated in six individual and

(23°C) for 6 and 24 h before dilution to 1.00 and 50.0 ng mL 1. The

pooled human plasma matrices.

QCs were kept on the bench‐top (23°C) before sample preparation
or in an autosampler (4°C) after sample preparation for 6 and 24 h.

Matrix factor and recovery
The absolute matrix factor (MF) of MLN0128 (or the IS) was determined by the mean peak area of MLN0128 (or the IS) at a specified
concentration in the extracted plasma matrix over that of MLN0128
(or the IS) at the concentration in the reconstitution solution. The IS
normalized MF was determined by the absolute MF of MLN0128 over
that of the IS. For this study, MLN0128 QCs at three concentrations

For the freeze–thaw study, the QCs were subjected to three freeze–
thaw cycles where the samples were frozen at −20°C for at least
24 h and thawed at room temperature (23°C) unassisted. For long‐
term storage study, the QCs were stored at −20°C and tested up to
2 months. For the above studies, the working solution of the IS
(50.0 ng mL 1) was prepared freshly on the day of experiment, and
added to each sample prior to sample extraction.

(0.250, 3.00 and 40.0 ng mL 1) with a fixed concentration of the IS
(5.00 ng mL 1) were prepared in six individual extracted plasma

RESULTS AND DISCUSSION

matrices and in the reconstitution solution.
The absolute recovery of MLN0128 (or the IS) was determined by
the mean peak area of MLN0128 (or the IS) at a specific concentration
in plasma matrix over that of MLN0128 (or the IS) at the concentration

Method development
Internal standard (IS)

in the extracted plasma matrix multiplying by 100%. The IS normalized

Owing to the lack of a heavy stable isotope of MLN0128,

recovery was determined by the absolute recovery of MLN0128 over

several commercially available structural analogs such as PP2

that of the IS multiplying by 100%. For this study, MLN0128 QCs at

(Sigma Aldrich, MO, USA), STK040263 and STK560245 (Vitas‐M
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Laboratory, Apeldoorn, Netherlands) were acquired and evaluated

these precursor ions were further fragmented in the collision cell into

as an IS for quantitation of MLN0128. STK040263 was chosen

predominant product ions at m/z 268 for MLN0128 and at m/z 127

for the subsequent work because it was rapidly and efficiently

for the IS. These predominant product ions were further confirmed

separated from MLN0128 by isocratic elution, whereas the

using an Agilent 6540 UHD Accurate‐Mass Q‐TOF LC/MS system

other structural analogs needed gradient elution to achieve the

(Agilent Technologies, Santa Clara, CA, USA) (data not shown), and

similar result.

the chemical structures of these ions were postulated (Figure 1a and b)
with the aid of Agilent Molecular Formula Generator and Molecular

Chemical properties of the analyte and the IS

Structure Coordinator software. In the case of product ion of the IS

Both MLN0128 and STK040263 are small, weak basic, organic mole-

(m/z 127), there was no structure suggested by the software; the

cules with monoisotopic masses of 309 and 225 g/mol (Figure 1).

postulated structure was hypothesized based on the chemical structure

The logP and pKa (of conjugate acid) of these compounds calculated

of the precursor ion and the found fragment formula (C10H7+) of the

by the ACD/Labs® software version 11.02 (Advanced Chemistry

product ion. MRM mode was adopted for quantitation of MLN0128

Development, Inc., Toronto, Ontario, Canada) are 2.35 and 3.77 for

with the mass transitions of m/z 310 → 268 for MLN0128 and m/z

MLN0128, and 1.36 and 4.20 for STK040263, respectively. The

226 → 127 for the IS, respectively.

logP values reveal the hydrophobic nature of these compounds,
whereas the pKa values of the conjugate acids suggest that the amino

Liquid chromatographic separation

groups of these compounds are protonated at low pH values. These

Owing to the hydrophobic nature of MLN0128 and STK040263,

chemical properties of the analyte and the IS guided us in the

reversed‐phase chromatographic columns were considered for analyt-

selections of solvent, mobile phase and chromatographic column.

ical separation. Several columns including Waters MS® XTerra C18,
Waters MS XTerra® C8 and Waters Atlantis® T3 (Waters Corporation,

Mass spectrometric detection
In this work, a triple quadrupole tandem mass spectrometer (MS/MS)

Milford, MA, USA) were tested. Among them, the Waters XTerra® MS
C18 column was chosen because it exhibited more symmetrical and

was used for analyte detection owing to its high selectivity and low

sharper peaks with improved resolution and signal‐to‐noise ratio in

limit of detection. Since MLN0128 and the IS were readily protonated

comparison to the others.

in the acidic mobile phase (pH 2.8), positive electrospray ionization (ESI+)

Because both MLN0128 and STK040263 are amine derivatives,

was chosen as a means of sample introduction. As shown in Figure 1,

they have tendency to adsorb on the silica solid support. The use of

MLN0128 and the IS readily produced protonated molecules

ammonium formate (10.0 mM at pH 2.8) as a component of the mobile

[MLN0128 + H]+ at m/z 310 (Figure 1a) and [IS + H]+ at m/z 226

phase not only promotes the formation of protonated analytes, but

(Figure 1b) in the ionization chamber of the mass spectrometer, and

also dynamically competes with the analyte and the IS to prevent

FIGURE 1

The mass spectra of precursor and product ions of MLN0128 and STK040263. Experimental conditions were the same as those
described in the section ‘Tandem mass spectrometry’
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chemical tailing on the column (Hansen, Helboa, & Lund, 1984;

Plasma sample preparation

McDowall, Pearce, & Murkitt, 1989). Furthermore, for achieving a

Both protein precipitation and liquid–liquid extraction (LLE) were

proper solvent strength and selectivity, a mixture of methanol and

investigated as plasma sample preparation methods in this work. Even

acetonitrile at a ratio of 85:15 (v/v) was used as another component

though protein precipitation was simpler to do, but it gave a lower ana-

of the mobile phase for rapid and efficient separation of the analyte

lyte recovery and stronger matrix effect in comparison to LLE (data not

and the IS.
For this work, the optimized liquid chromatographic separation

shown).
For the LLE study, several organic solvents such as MTBE, ethyl

was obtained using a Waters XTerra® MS C18 column, and a

acetate, isopropanol and hexane were investigated as extraction

mobile phase consisting 60% of ammonium formate (10.0 mM,

solvents for plasma sample either alone or in combination. While

pH 2.8) and 40% methanol–acetonitrile (85/15, v/v) pumped at a

MTBE showed the highest extraction efficiency, hexane yielded

flow rate of 0.300 mL min 1. The total run time was 4.00 min

none. Therefore, MTBE was chosen as the organic solvent for the

with retention times of 1.95 and 2.94 min for the IS and MLN0128,

sample preparation by LLE. Figure 3 shows the matrix effect of

respectively (Figure 2).

the MTBE‐extracted blank plasma injected by the autosampler on

FIGURE 2 The mass chromatograms of
MLN0128 and IS in human plasma. (a) double
blank plasma (with neither MLN0128 nor IS);
(b) single blank plasma (with IS only at
50.0 ng mL 1); and (c) at LLOQ (MLN0128 at
0.100 ng mL 1 and IS at 50.0 ng mL 1). Experimental conditions were the same as those
described in the sections ‘Liquid chromatography’ and ‘Tandem mass spectrometry’
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FIGURE 3

The mass chromatograms of post‐
column infusion of MLN0128. (a) injection of
10.0 μL mobile phase; and (b) injection of
10.0 μL MTBE extract of blank human plasma.
The LC–MS conditions were the same as
those in Figure 2, and the post‐column infusion of MLN0128 (500 ng mL 1) was carried
out by an integrated syringe pump through a
three‐port mixing tee at a flow rate of
10.0 μL min 1

the analytical signal of analyte standard solution (i.e. the baseline

solution (10 mM, pH 2.8) was chosen as the reconstitution solution of

signal) via post‐column infusion, which revealed that the matrix effect

the subsequent work.

(i.e. signal elevation or suppression) mainly occurred in the retention
times between 0.80 and 1.50 min, and did not affect the analytical

Method validation

signals of the IS and MLN0128 at the peak values of 1.95 and

Selectivity and LLOQ

2.94 min, respectively.

The selectivity and the LLOQ of the method were examined in this
work. As illustrated by the representative mass chromatograms of

Reconstitution solution

the double blank plasma (Figure 2a) recorded at the same mass

During plasma sample preparation, MTBE extract containing

transitions of MLN0128 and the IS, while no detectable interference

the analyte and the IS was dried under nitrogen gas, and the

was observed at the same retention time of IS, a tiny endogenous

resultant residue was reconstituted in a reconstitution solution

interferent peak was detected near the retention time of MLN0128.

for the subsequent LC–MS/MS analysis. For this work, the

The representative mass chromatograms of the single blank plasma

mobile phase was initially used as the reconstitution solution to

(Figure 2b) showed that the interferent was not a part of the IS. Since

reconstitute the dried residue; however, it produced a cloudy

the mean peak area of the endogenous interferent from six different

solution (colloidal suspension) and caused injection problems. In an

individual double blank plasmas was <6% of that of MLN0128 at the

attempt to remove the cloudiness of the reconstitute, various ratio

LLOQ (Figure 2c), which was much lower than the limit set by US Food

of acetonitrile–methanol as the organic components of the mobile

and Drug Administration (≤20%), the interferent was tolerated at the

phase, and various buffer compositions (e.g. ammonium formate,

LLOQ in this method. The LLOQ of this method was 0.100 ng mL

ammonium acetate or ammonium bicarbonate) and concentrations

for MLN0128, which had accuracy and precision ≤ ± 9 and ≤7%

(e.g. 5.00–20.0 mM) as the aqueous component of the mobile

(Table 1), assessed by five replicate measurements of six plasma cali-

phase were tested, and showed no change on the cloudiness of the

brators at LLOQ each prepared by a different individual blank plasma.

1

reconstitute. Eventually, the use of lower percentage of organic
solvent in reconstitution solution [i.e. 10% MeOH with 90%

Matrix effect and recovery

ammonium formate solution (10 mM, pH 2.8)] resulted in clear sample

Matrix effect was assessed by the MF of MLN0128 at three QC con-

solution. Therefore, 10% MeOH with 90% ammonium formate

centrations in six individual plasma matrices. As shown in Table 2,

TABLE 1

Accuracy and precision of MLN0128 at LLOQ in six individual lots of human plasma (n = 5)

Plasma matrix
Lot 1

Nominal [MLN0128] (ng mL−1)

Mean measured [MLN0128] (ng mL−1)

SD (ng mL−1)

Precision (CV, %)a

Accuracy (RE, %)b

0.100

0.104

0.001

1

4

Lot 2

0.100

0.101

0.004

4

1

Lot 3

0.100

0.093

0.003

3

−7

Lot 4

0.100

0.102

0.007

7

2

Lot 5

0.100

0.096

0.003

3

−4

Lot 6

0.100

0.109

0.003

3

9

a

CV (Standard deviation/mean) × 100%.

b

RE [(measured

nominal)/(nominal)] × 100%.
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TABLE 2

Matrix factors of MLN0128 QCs in six individual lots of
human plasma (n = 5)
Plasma
matrix
Lot 1

[MLN0128]
(ng mL−1)

MFMLN0128
± SDa

0.250
3.00
40.0

Lot 2

1.02 ± 0.02

0.94 ± 0.02

1.08 ± 0.04

absolute recoveries of MLN0128 and the IS were 79–84 and

1.02 ± 0.03

0.95 ± 0.01

1.07 ± 0.02

81–84%, respectively, and the IS normalized recoveries were

0.99 ± 0.02

0.96 ± 0.01

1.04 ± 0.02

95–100%. These results indicated that MTBE extraction used was

0.96 ± 0.03

0.91 ± 0.02

1.05 ± 0.05

efficient and consistent for the recovery of MLN0128 and the IS

0.98 ± 0.01

1.02 ± 0.03

from human plasma samples.

0.98 ± 0.01

0.98 ± 0.01

1.00 ± 0.02

0.250

0.98 ± 0.06

1.00 ± 0.01

0.98 ± 0.05

3.00

0.99 ± 0.01

0.98 ± 0.01

1.01 ± 0.02

0.93 ± 0.01

0.97 ± 0.01

0.96 ± 0.01

0.250

1.04 ± 0.06

1.02 ± 0.01

1.01 ± 0.06

3.00

1.01 ± 0.01

1.00 ± 0.01

1.01 ± 0.01

0.250
3.00

0.96 ± 0.01

0.95 ± 0.02

1.01 ± 0.01

0.99 ± 0.04

0.99 ± 0.00

1.00 ± 0.04

0.99 ± 0.01

0.97 ± 0.02

1.02 ± 0.01

0.97 ± 0.01

0.95 ± 0.01

1.02 ± 0.02

0.250

1.0 ± 0.1

1.03 ± 0.01

1.0 ± 0.1

3.00

0.98 ± 0.02

0.96 ± 0.03

1.02 ± 0.02

0.94 ± 0.02

0.92 ± 0.03

1.02 ± 0.02

40.0
Lot 6

in pooled human plasma are summarized in Table 3. The

1.00 ± 0.02

40.0
Lot 5

The recoveries of MLN0128 at three different QC concentrations

MFIS ± SDb

0.250

40.0
Lot 4

was used as organic solvent for the analyte extraction.

IS normalized
MF ± SDc

3.00
40.0
Lot 3

negligible in the measurements of MLN0128 and the IS when MTBE

40.0

Calibration curve
The mean linear regression equation based on three individual calibration curves in three days was y = 0.516 (±0.005)x + 0.015 (±0.004) over
the range of 0.100–50.0 ng mL

1

with a correlation coefficient of

0.999. As shown in Table 4, the accuracy and precision of individual
plasma calibrators were ≤ ± 6% and ≤7%, respectively.

Assay accuracy, precision and dilution integrity
As shown in Table 5, the intra‐assay accuracy and precision were ≤ ± 4
and ≤8%, and the inter‐assay accuracy and precision were ≤ ± 4 and
≤2%, respectively, indicating that the method developed was accurate
and precise. The dilution studies showed that the intra‐assay accuracy

a

MFMLN0128 (mean peak area of MLN0128 in the extracted plasma
matrix)/(mean peak area of MLN0128 in the reconstitution solution).
b

MFIS (mean peak area of the IS in the extracted plasma matrix)/(mean
peak area of the IS in the reconstitution solution).

and precision were ≤ ± 3 and ≤3%, and the inter‐assay accuracy and
precision were ≤ ± 1 and ≤1%, indicating the integrity of plasma samples could be preserved in sample dilution.

c

IS normalized MF MFMLN0128/MFIS.

Stability studies of MLN0128
the absolute MFs of MLN0128 and the IS were 0.93–1.04 and

The stability studies for MLN0128 were conducted and the data are

0.91–1.03, respectively, and the IS normalized MFs were 0.96–1.08.

summarized in Table 6. The stock solutions and plasma QCs were

These data revealed that the matrix effect of human plasma was

found to be stable by free standing on bench‐top at room temperature

TABLE 3

Recovery of MLN0128 in pooled human plasma (n = 5)

[MLN0128] (ng mL−1)

RecoveryMLN0128a ± SD (%)

RecoveryISb ± SD (%)

IS Normalized recoveryc ± SD (%)

0.250

84 ± 3

84 ± 1

100 ± 3

3.00

80 ± 2

84 ± 3

95 ± 3

40.0

79 ± 1

81 ± 2

98 ± 1

a

RecoveryMLN0128 [(mean peak area of MLN0128 in plasma matrix)/(mean peak area of MLN0128 in extracted plasma matrix)] × 100%.

b

RecoveryIS [(mean peak area of IS in plasma matrix)/(mean peak area of IS in extracted plasma matrix)] × 100%.

c

IS normalized recovery

[(RecoveryMLN0128)/(RecoveryIS)] × 100%.

PA mean peak area.

TABLE 4

Accuracy and precision of plasma MLN0128 calibrators in three validation batches over three different days

Nominal [MLN0128] (ng mL−1)

Measured [MLN0128] (ng mL−1)

SD (ng mL−1)

0.100

0.101

0.008

7

0.200

0.203

0.006

3

1

0.500

0.49

0.02

3

−1

1.00

0.978

0.006

0.6

−2

2.50

2.5

0.1

3

5.00

4.89

0.04

0.6

−2

10.0

9.9

0.3

2

−1

Precision (CV, %)

Accuracy (RE, %)
0.6

1

25.0

26.4

0.5

2

6

50.0

48.8

0.7

1

−2

008
TABLE 5

Intra‐ and inter‐assay accuracy and precision of MLN0128 in pooled human plasma (n = 5)

Nominal [MLN0128] (ng mL−1)

Measured [MLN0128] (ng mL−1)

SD (ng mL−1)

CV, %

RE, %

Intra‐assaya
0.250

0.249

0.007

3

−0.6

3.00

2.94

0.03

1

−2

40.0

38

3

8

−4

250c

257

7

3

3

Inter‐assay

b

0.250

0.243

0.005

2

−3

3.00

2.88

0.05

2

−4

0.6

1

−4

4

1

1

40.0

38.3

c

253

250
a

Measured by five replicate measurements of each QC sample within a validation batch.

b

Measured by five parallel measurements of five identical QC samples at each concentration over three validation batches.

c

Dilution QC was measured after a 10‐fold dilution with pooled blank human plasma and the reported concentration was back calculated by multiplying a
factor of 10.

TABLE 6

Stabilities of MLN0128 under various test conditions (n = 5)
Recovery ± SD (%)

Test conditions
Bench‐top

Bench‐top

Autosampler

Three freeze thaw cycles

Long term (60 days)

Temperature (°C)

MLN0128

23

4
−20 23
−20

100 ± 1

Stock solutionb

101 ± 1

99 ± 1

Low QCc

98 ± 4

105 ± 5

High QCc

94 ± 1

97 ± 2

Low QC

94 ± 3

104 ± 2

High QC

93 ± 1

91 ± 1

Low QC

102 ± 2

94 ± 1

High QC

99 ± 1

101 ± 1

92 ± 1

Low QC

101 ± 1

High QC

95 ± 1

a

The concentration of MLN0128 stock solution was 1.00 mg mL 1, which was measured by serial dilution to 1.00 ng mL

b

24 h

a

Stock solution

23

6h

1

The concentration of MLN0128 stock solution was 1.00 mg mL , which was measured by serial dilution to 50.0 ng mL

1

in mobile phase.

1

in mobile phase.

c

The concentration of plasma low and high QCs were 0.250 and 40.0 ng mL 1, respectively.

for at least 24 h prior to sample preparation with recoveries of 99–101

proposals were not funded eventually, the validated method may

and 94–105%, respectively. The plasma QCs were also stable for at

be used by the scientific community for preclinical and clinical studies

least 24 h in autosampler set at 4°C post sample preparation with

of MLN0128.

recoveries of 91–104%. The recoveries of plasma QCs after three
freeze–thaw cycles were 92–102%, and after long‐term (2 months)
storage at −20°C recoveries were 95–101%. These studies showed
that there were no significant losses of MLN0128 under the test
conditions.

CO NC LUSIO NS
A rapid and selective LC–MS/MS method has been developed for the
quantitative determination of MLN0128 in human plasma. In this

Method application

method, MLN0128 and the IS were extracted from human plasma by
an LLE procedure, and separated by reversed‐phase chromatography

The method developed was intend to support the proposed

with isocratic elution. Quantitation of MLN0128 was carried out by

clinical studies of MLN0128 in a ‘Randomized Pilot Phase 0 and

internal calibration and positive electrospray ionization tandem mass

FLT‐PET/MRI Imaging Biomarker Study of MLN0128 in Recurrent

spectrometry operated in MRM mode. This method has been validated

Glioblastoma Multiforme’ and a ‘Phase 1 Study of MLN0128

according to US Food and Drug Administration guidance for industry

with Bevacizumab’ from the Case Comprehensive Cancer Center in

on bioanalytical method validation. It may be used in clinical studies

response to the NCI/CTEP solicitation in 2013. Even though both

of MLN0128 in human.
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